Diametric Capital, LP Zymeworks Inc. Transaction History

Diametric Capital, LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	BUY	$4.82 - $7.7 $144,609 - $231,015	30,002 New	30,002 $159,000
Q3 2020 Nov 13, 2020	SELL	$29.21 - $46.58 $528,993 - $843,563	-18,110 Closed	0 $0
Q2 2020 Aug 14, 2020	SELL	$33.67 - $40.0 $113,097 - $134,360	-3,359 Reduced 15.65%	18,110 $653,000
Q1 2020 May 15, 2020	SELL	$24.28 - $49.8 $665,879 - $1.37 Million	-27,425 Reduced 56.09%	21,469 $762,000
Q4 2019 Feb 14, 2020	SELL	$24.84 - $45.46 $766,140 - $1.4 Million	-30,843 Reduced 38.68%	48,894 $2.22 Million
Q3 2019 Nov 13, 2019	BUY	$22.78 - $29.08 $1.82 Million - $2.32 Million	79,737 New	79,737 $1.98 Million

296K

Ticker ZYME
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,694,400
Market Cap $917M
Description
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas...

Get notified when there are updates to the investment portfolio of Diametric Capital, LP, based on Form 13F filings with the SEC.

Stay updated on Diametric Capital, LP with notifications on news.